Altimmune Inc ( ALT ) rallied over 60% from lows in April 2025, to highs in June 2025, prior to the 24-week data from its phase 2b IMPACT trial of pemvidutide in metabolic-dysfunction associated steatohepatitis (MASH). A key catalyst lies aheadScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Discl ...